A single blind, randomised, placebo controlled, single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of GSK958108 in healthy male subjects.
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2017
At a glance
- Drugs GSK 958108 (Primary)
- Indications Premature ejaculation
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 27 Oct 2008 Status changed from not yet recruiting to completed.
- 19 May 2008 New trial record.